Brightcove Powers Japan’s Newest Streaming Service, J:COM’s “Animal Watch”
Brightcove (NASDAQ: BCOV), the world’s most trusted streaming technology company, announced today that it is welcoming JCOM Co., Ltd. (J:COM), Japan’s largest cable TV company, as a new customer. As the streaming technology partner for J:COM, Brightcove is powering the media company’s newest streaming service, Ikimono Watch (“Animal Watch”), which plans to broadcast content from across Japan’s zoos and aquariums.
“J:COM is Japan's biggest and most respected cable company. We’re honored to collaborate closely with them on this new venture to provide a high-quality and engaging streaming experience for viewers across Japan,” said Chiyo Yanagita, Country Manager, Brightcove Japan. “J:COM’s decision to choose Brightcove is a testament to our platform’s reliability, security, and ability to scale and grow with the service.”
The new streaming app, Ikimono Watch, works with J:COM set-top boxes and was built with Brightcove’s Android software development kit (SDK). Brightcove’s Video Cloud securely houses all of the video content sourced from zoos and aquariums across Japan, and the Video Cloud API is integrating with the app’s content management system (CMS) to retrieve content and ensure a smooth, efficient viewing experience.
“By choosing Brightcove's platform, we were able to ensure a smooth launch for our ‘Ikimono Watch’ project. The company’s experience in video distribution and handling various types of content has contributed greatly to the efficient and successful introduction of our new streaming service. Video Cloud is indispensable to the strategy of Ikimono Watch, and we look forward to its future growth,” shared Mr. Masaki Uchiyama, J:COM General Manager, Next Gen. Platform Development Department, Service Planning Division.
J:COM joins a roster of media companies that rely on Brightcove to power their streaming capabilities, including Acun Medya, AMC Networks, BBC Studios, Canela Media, LIXIL Corporation, MotoAmerica, NHL, One31, REELZ, SBT TV, SHISEIDO, SKY Mexico, The Academy of Motion Pictures and Sciences, The National Academy of Television Arts & Sciences, Wacoal and Yahoo.
For more information, visit Brightcove.com.
About JCOM Co., Ltd.
Established in 1995, JCOM Co., Ltd.(J:COM) is Japan's largest multiple system and multiple channel operator. In system operation, J:COM provides cable television, high speed internet access, telephony, mobile, electric power service, and services based on IoT devices to customers through 11 consolidated subsidiaries at the local level serving 5.68million subscribing households in Sapporo, Sendai, Kanto, Kansai, and Kyushu-Yamaguchi regions. The number of serviceable households or “homes passed” in J:COM franchise areas is 22.42 million. In channel operation, J:COM invests in and operates 14 thematic channels which are provided to CATV, satellite and telecom operators.
※ The above subsidiaries and household figures are as of Mar 31, 2024.
About Brightcove Inc.
Brightcove creates the world’s most reliable, scalable, and secure streaming technology solutions to build a greater connection between companies and their audiences, no matter where they are or on which devices they consume content. In more than 60 countries, Brightcove’s intelligent video platform enables businesses to sell to customers more effectively, media leaders to stream and monetize content more reliably, and every organization to communicate with team members more powerfully. With two Technology and Engineering Emmy® Awards for innovation, uptime that consistently leads the industry, and unmatched scalability, we continuously push the boundaries of what video can do. Follow Brightcove on LinkedIn, X, Facebook, Instagram, Threads, and YouTube. Visit Brightcove.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240606741108/en/
Contact information
Media Contacts
Brightcove
Joseph J. Nuñez
Director of Global Communications and Public Relations
jnunez@brightcove.com
JCOM Co., Ltd.
Public Relations
TEL：080-5965-0001（Uchikawa)
E-Mail：uchikawam@jupiter.jcom.co.jp
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Announces US FDA Approval of ALYFTREK ™ , a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis20.12.2024 21:46:00 CET | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment of cystic fibrosis (CF) in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is responsive to ALYFTREK. See below for Important Safety Information, including a Boxed Warning. “ALYFTREK is our fifth CFTR modulator to secure FDA approval and represents another significant milestone in our journey to serially innovate and to improve the lives of people living with cystic fibrosis,” said Reshma Kewalramani, M.D., Chief Executive Officer and President of Vertex. “Our north star for more than 20 years has been to address the underlying cause of cystic fibrosis, treat more people with this disease, and bring more people to normal le
Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non- F508del TRIKAFTA-Responsive Variants20.12.2024 21:35:00 CET | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 2 and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation that is responsive to TRIKAFTA based on clinical and/or in vitro data. In addition, safety information on liver injury and liver failure has been updated from warnings and precautions to a boxed warning. With this approval, 94 additional non-F508delCFTR mutations have been added to the TRIKAFTA label, and approximately 300 additional people with CF in the U.S. are now eligible for a medicine to treat the underlying cause of their disease for the first time. “Since its first approval in 2019, TRIKAFTA has had a transformative impact on tens of thousands of people living with cystic fibrosis,” sai
HSBC Continental Europe Enters Into a Memorandum of Understanding Regarding Potential Sale of HSBC Assurances Vie (France) to Matmut Société d’Assurance Mutuelle20.12.2024 20:32:00 CET | Press Release
Regulatory News: HSBC Continental Europe has signed a Memorandum of Understanding (‘MOU‘) regarding the potential sale of its French life insurance business, HSBC Assurances Vie (France), to Matmut Société d’Assurance Mutuelle (‘Matmut’) (the “Potential Transaction”). HSBC Assurances Vie (France) provides a wide range of life insurance solutions and services, with over 20 billion euros of outstanding assets, net income1 of 77 million euros and a Solvency II ratio of 287% in 2023. As part of the Potential Transaction, HSBC Continental Europe and Matmut would enter into a long-term arrangement for HSBC Global Asset Management (France) to continue to partner with HSBC Assurances Vie (France). HSBC Assurances Vie (France) will continue its existing distribution arrangements. The Potential Transaction would provide customers and employees of HSBC Insurance Life (France) with the opportunity to join one of the leading French mutual insurance groups, which is in full development, and forms pa
SBC Medical Group Co., Ltd. Sells Two Subsidiaries20.12.2024 13:00:00 CET | Press Release
On December 17, 2024, SBC Medical Group Holdings Incorporated (“SBC Medical”, or the “Company”), announced that its subsidiary, SBC Medical Group Co., Ltd. (hereinafter referred to as "SBCMG"), has decided to sell all shares of its subsidiaries, SBC Kijimadaira Resort Co., Ltd. (hereinafter referred to as "Kijimadaira") and Skynet Academy Co., Ltd. (hereinafter referred to as "SNA"), as outlined below. The decision to sell these subsidiaries was made to concentrate SBCMG's management resources on its core medical services business, in line with its strategy of prioritizing and focusing on key business areas. The subsidiaries being sold operate in the following industries: Kijimadaira: Ski resort operations SNA: Flight training operations The shares will be sold to a company wholly owned by Yoshiyuki Aikawa, the CEO of the Company. Since this transaction constitutes a related party transaction, it was deliberated and approved by the Company’s Board of Directors and Audit Committee. To e
Aarhus University: New Global Study Sheds Light on the Learning Crisis: Three Years After COVID-1920.12.2024 13:00:00 CET | Press Release
TIMSS 2023 has revealed an alarming global learning crisis exacerbated by the COVID-19 pandemic. Compared to the long term trend in progress in mathematics and science achievement has not only stalled but reversed when taking school closures into account, with the most vulnerable students facing the steepest losses. Key Findings Global Achievement Decline: A 0.11 standard deviation drop in student performance reflects the pandemic's lasting impact. Disproportionate Impact: Low performers, girls, and language minorities faced losses up to twice the average (0.22 standard deviations), deepening existing inequities. Regional Variations: Countries with prolonged school closures and limited remote learning resources experienced the steepest declines. Why This Matters School closures disrupted the education of over one billion children worldwide, with disadvantaged students suffering the most. “The widening gender gap in STEM fields is particularly troubling,” said Christian Kjeldsen, incomi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom